Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD.

Original languageEnglish (US)
Pages (from-to)1382-1391
Number of pages10
JournalPain
Volume159
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Nociception
Sickle Cell Anemia
Ligands
Pain
Morphine
Analgesics
Posterior Horn Cells
Nociceptors
mu Opioid Receptor
Chemokine Receptors
Hyperalgesia
Constipation
Pain Management
Chronic Pain
Respiratory Insufficiency
Opioid Analgesics
Transgenic Mice
Spinal Cord
Cytokines
Therapeutics

Keywords

  • CCR5
  • Hyperalgesia
  • Mu-opiate receptor
  • Tolerance

PubMed: MeSH publication types

  • Journal Article

Cite this

Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease. / Cataldo, Giuseppe; Lunzer, Mary M.; Olson, Julie; Akgun, Eyup; Belcher, John D; Vercellotti, Gregory M; Portoghese, Philip S; Simone, Donald A.

In: Pain, Vol. 159, No. 7, 01.07.2018, p. 1382-1391.

Research output: Contribution to journalArticle

@article{d5b58cb72053476eb9c34ff01937d017,
title = "Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease",
abstract = "Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD.",
keywords = "CCR5, Hyperalgesia, Mu-opiate receptor, Tolerance",
author = "Giuseppe Cataldo and Lunzer, {Mary M.} and Julie Olson and Eyup Akgun and Belcher, {John D} and Vercellotti, {Gregory M} and Portoghese, {Philip S} and Simone, {Donald A}",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/j.pain.0000000000001225",
language = "English (US)",
volume = "159",
pages = "1382--1391",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease

AU - Cataldo, Giuseppe

AU - Lunzer, Mary M.

AU - Olson, Julie

AU - Akgun, Eyup

AU - Belcher, John D

AU - Vercellotti, Gregory M

AU - Portoghese, Philip S

AU - Simone, Donald A

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD.

AB - Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD.

KW - CCR5

KW - Hyperalgesia

KW - Mu-opiate receptor

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=85057804990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057804990&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000001225

DO - 10.1097/j.pain.0000000000001225

M3 - Article

VL - 159

SP - 1382

EP - 1391

JO - Pain

JF - Pain

SN - 0304-3959

IS - 7

ER -